FDA reviewing Valeant psoriasis candidate IDP-118

The Ortho Dermatologics unit of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said FDA accepted for review an NDA for IDP-118 to treat plaque psoriasis. Its PDUFA date is June 18, 2018...